Table 7.
Studies examining synbiotics for prevention/treatment of allergic rhinitis.
| # | Author and Publication Date | Country | Type of Study | Number of Patients | Age | Type of Synbiotic | Administration Duration of Synbtics | Long-Term Follow Up | Effect |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Dehnavi et al., 2019 [70] | Iran | placebo-controlled, double-blind RCT | n = 20 | 9 up to 53 years |
S. thermophilus, B. spp., L. spp., FOS Doses: not written |
2 months | Total of 6 months | Significant reduction in IL-17 gene expression following administration of symbiotic. Clinical symptoms and quality of life were improved with immunotherapy. Synbiotics did not have additional effects |
| 2 | Jalali et al., 2019 [51] | Iran | Crossover RCT | n = 152 | Adults; 30.1 ± 7.6 years | seven different Gram-positive organisms: 9 × 109 cfu/g lyophilized lactobacilli (L. acidophilus, L. casei, L. delbrueckii subsp. L. bulgaricus, and L. rhamnosus), 1.25 × 1010 of bifidobacteria (B. longum, and B. breve), and 1.5 × 10−10 of S. salivarius subsp. thermophilus and 38.5 mg FOS | 4 months | Total 2 months | Addition of probiotics to budesonide significantly improved QoL in persistent AR patients |
Legend. #: number; RCT, randomized controlled trial; spp., species; cfu, colony-forming unit; CI, confidence interval; RR, relative risk; L: Lactobacillus; B: Bifidobacterium; S; Stretococcus; FOS; fructo-oligosaccharide.